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The wide general publication of a putative genetic test for athletic supremacy is clearly an abuse
of genetics and reveals an undercurrent of hucksterism in biomedical science.
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When we agreed to compose a series of commentaries for
Genome Medicine, we vowed to stick with the science and
discuss interesting and important developments in genome
medicine. We started with genome-wide association studies,
and plan commentaries on gene therapy and cancer genetics
to be followed by a series of commentaries on various
genetic diseases, from Crohn’s disease to disorders of eye
development. We did not intend to launch into ad hoc
discussions of ethical or policy issues because we do not
consider our own opinions on scientific or clinical right and
wrong to be more valid than those of any thoughtful
professional. We do not appreciate lectures on morality so,
we concluded, why should we inflict them on our readers?
But something snapped in both of us when we read a front
page story in the New York Times of 30 November 2008.
There for all to behold was a new gene test, this one for a
gene that may have some vague relationship to muscle
activity. The test is being marketed to the unwary who may
wish to determine whether their fertilized egg, fetus, or
newborn is endowed with the “right” gene to support a
future in certain kinds of athletics.
To test our own immediate negative reactions we asked one
of our colleagues, a distinguished molecular, population and
clinical (pediatric) geneticist, to read the New York Times
article and give us his impressions. He had seen some of the
reports on the genetics as well as the article and his response
was as follows:
“Now I think I need some antihypertensives to avoid a
stroke. The association with athletic ability (I seem to
recall) had some intriguing hints but was very confusing to
me (different effects for endurance versus speed, elite
athlete versus non-elite, male versus female). I also think
there are other studies, not mentioned in the NYT article,
that don’t back it up. Plus, there are other reasons it might
have been a false positive. But, even if it were completely
valid, there is a huge distinction between a valid
association and marketing a genetic test to parents of
potential youth soccer players. Whatever happened to
having your child try out a bunch of activities and seeing
what your child likes and is good at?
I think the test is worthless and probably misleading.”
The gene in question is ACTN3, a member of the muscle
α-actinin gene family. Polymorphisms of this gene are the
subjects of about 50 reports, largely in the sports medicine
literature. Most of the articles make rather weak claims of
associations of certain polymorphisms with either muscle
strength or speed in athletes. Some of the reports dispute the
associations. To make decisions on the future of a child
based on such a test is clearly irresponsible.
This is not to say that genetics plays no role in athletic
performance. A look at the dominance of Kenyan runners in
marathons is all one needs to be persuaded that genetic
endowment together with training plays a very strong role inathletic performance capacity. But to rely in any way on a
single genetic test to predict such performance is absurd.
The purveyors of such a test are simply preying on the
anxieties and gullibility of parents who have no biomedical
training and are irrationally desperate to achieve success for
their children. The marketing of such a test conjures up the
ultimate abuse of genetic medicine, a nightmare scenario in
which technicians sort through fertilized eggs, discarding
embryos that don’t have the ‘right’ genetic stuff to be
potential football stars.
We do not see ourselves as moralizing physicians encum-
bered by some religious or high-minded zeal, or unwilling to
explore controversial procedures. We have, in fact, devoted
considerable effort to the development of prenatal diagnostic
tests for the serious hemoglobinopathies such as thalassemia
or sickle cell disease because we believe that parents should
be able to plan a family without fear. But we share with most
of our neighbors a deep reverence and respect for the fetus,
the mother and the child. We would never devise a prenatal
test for a trivial purpose, because that might lead to abortion
for no worthy reason. We include as trivial the gender of a
fetus, unless the information would inform the prospective
parents about the risk of an X-linked disorder the gene for
which had not yet been determined. Nor would we coun-
tenance a weak (read worthless) genetic test for anything
that might be stupidly used to pigeon hole the academic or
athletic future of a child. We consider conclusions drawn
from single genetic tests to establish probabilities of complex
traits both foolish and venial: venial because the hucksters
and mountebanks who promote the tests do so knowing that
they are selling snake oil.
Perhaps we are particularly sensitive when we see such
nonsense promulgated by so-called ‘experts’ because we
have been forced to accept that our own profession is in fact
infiltrated by a few unscrupulous and greedy colleagues who
are in ‘the game’ to get rich and famous and not to provide
the very best they can for patients who suffer from serious
disorders. The infiltration can come very close to home. At
this very moment we have prominent faculty members who
stand accused of selling out their reputations to drug
companies in order to help the companies market drugs of
disputed value for children. They accept huge consulting fees
from such companies and then piously maintain that they
are above the influence of mere pelf.
In no way does our disgust with such outliers reduce our
respect for, and indeed reliance on, the pharmaceutical or
biotechnology industries. We are thoroughly persuaded by
our own experience that these two industries have made huge
contributions to medicine worldwide. Without their brilliant
science, their medicinal chemistry and their capacity to
perform clinical trials, we would be set back decades. But the
outliers in the industries and on faculties bring shame and
opprobrium as well as excessive regulation upon all of us. We
are in a very tough period in investigative medicine right
now. Funds are in short supply, just as our knowledge is
expanding. We are on the threshold of major discoveries in
the chronic diseases that afflict our society. False claims ruin
our stature in society, turn government against us and, worst
of all, destroy the confidence of our patients.
So we are angry when we read articles like the great muscle
gene prevarication. We just don’t want to co-inhabit clinical
science with ‘colleagues’ for whom we have no respect. So we
took this opportunity to say so loud and clear. Genetics has a
huge potential in medicine and public health, but that
potential will not be realized if genetics is twisted to put
money and power ahead of quality patient care.
We had to get that anger off of our chests. Now we can
return to the science.
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